Content about Sulfoxides

April 4, 2013
Allergy Relief 2013

The March/April 2013 Allergy Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Claritin-D, Allegra-D, Zyrtec-D, Benadryl-D, Advil Allergy and Congestion Relief, UrgentRx Allergy Attack, Hyland's Seasonal Allergy Relief, Similasan's Nasal Allergy Relief and Boiron's Sabadil.

The March/April 2013 Allergy Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Claritin-D, Allegra-D, Zyrtec-D, Benadryl-D, Advil Allergy and Congestion Relief, UrgentRx Allergy Attack, Hyland's Seasonal Allergy Relief, Similasan's Nasal Allergy Relief and Boiron's Sabadil.

March 27, 2013
FDA approves Aciphex Sprinkle capsules

The Food and Drug Administration has approved a treatment made by Eisai for gastroesophageal reflux disease in children ages 1 year to 11 years, the drug maker said.

WOODCLIFF LAKE, N.J. — The Food and Drug Administration has approved a treatment made by Eisai for gastroesophageal reflux disease in children ages 1 year to 11 years, the drug maker said.

Eisai announced the approval of Aciphex Sprinkle (rabeprazole sodium) delayed-release capsules.

January 28, 2013
Amneal, South Korea-based Hanmi enter GERD drug deal

U.S. generic drug maker Amneal Pharmaceuticals has entered a deal with South Korean drug maker Hanmi Pharmaceutical to acquire exclusive distribution rights for a Hanmi drug used for treating gastroesophageal reflux disease, Amneal said Monday.

BRIDGEWATER, N.J. — U.S. generic drug maker Amneal Pharmaceuticals has entered a deal with South Korean drug maker Hanmi Pharmaceutical to acquire exclusive distribution rights for a Hanmi drug used for treating gastroesophageal reflux disease, Amneal said Monday.

January 28, 2013
Vitamins & Supplements 2013

The January/February 2013 Vitamins & Supplements Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Centrum, One-A-Day, NatureMade, VitaFusion, Alive, VirMax-T, MoveFree, Bioglan and Voots products.

The January/February 2013 Vitamins & Supplements Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Centrum, One-A-Day, NatureMade, VitaFusion, Alive, VirMax-T, MoveFree, Bioglan and Voots products.

Click here for the complete guide.

January 17, 2013
Pennsylvania man wins Prilosec OTC Wildberry sweepstakes

Out of more than 200,000 entries, Procter & Gamble named "William R." of Pennsylvania winner of the ultimate sports pack as part of Wild American Flavor Sweepstakes sponsored by Prilosec OTC Wildberry.

CINCINNATI — Out of more than 200,000 entries, Procter & Gamble named "William R." of Pennsylvania winner of the ultimate sports pack as part of Wild American Flavor Sweepstakes sponsored by Prilosec OTC Wildberry.

The contestant won a once-in-a-lifetime trip to three of the country’s "most flavorful" cities that host the biggest sporting events in America, including tickets to the Super Bowl, NASCAR's Daytona 500 and the NCAA basketball championship game in Atlanta, travel and accommodations and $5,000. 

December 4, 2012
FDA accepts application for GERD drug in children

The Food and Drug Administration will review an acid-reflux drug made by Eisai for use in children, the drug maker said.

WOODCLIFF LAKE, N.J. — The Food and Drug Administration will review an acid-reflux drug made by Eisai for use in children, the drug maker said.

Eisai said the FDA accepted its application for AcipHex delayed-release sprinkle capsules in the 5-mg and 10-mg strengths for healing of gastroesophageal reflux disease, and maintenance of healing of GERD and improvement of symptoms in children ages 1 year to 11 years.

The FDA expects to have the application reviewed by March 27, 2013. The drug is currently approved in the 20-mg strength for adolescents and adults.

November 28, 2012
Cough, cold and flu

The November/December 2012 Cough, Cold and Flu Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Mucinex, Vicks, Advil, Theraflu, Delsym, St. Joseph, Hyland's Similasan and Zicam products.

The November/December 2012 Cough, Cold and Flu Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Mucinex, Vicks, Advil, Theraflu, Delsym, St. Joseph, Hyland's Similasan and Zicam products.

Click here for the complete guide.

October 16, 2012
Perrigo wins tentative approval for generic Zegerid OTC

Perrigo has received tentative approval from the U.S. Food and Drug Administration for its abbreviated new drug application to market over-the-counter omeprazole and sodium bicarbonate capsules in the 20-mg/1,100-mg strength, the store-brand equivalent to Merck's Zegerid OTC.

ALLEGAN, Mich. — Perrigo has received tentative approval from the U.S. Food and Drug Administration for its abbreviated new drug application to market over-the-counter omeprazole and sodium bicarbonate capsules in the 20-mg/1,100-mg strength, the store-brand equivalent to Merck's Zegerid OTC.

Zegerid OTC (omeprazole and sodium bicarbonate capsules 20 mg/1,100 mg), a proton-pump inhibitor indicated to relieve frequent heartburn, had sales of approximately $42 million through food, drug and mass merchandisers for the lastest 12 months.

October 4, 2012
Digestive Aids

The September/October 2012 Digestive Aids Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Tums, Di-Gel, Zantac, Pepcid AC, Prilosec OTC, Prevacid 24HR, Dulcolax, Senokot and Pepto-Bismol.

The September/October 2012 Digestive Aids Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Tums, Di-Gel, Zantac, Pepcid AC, Prilosec OTC, Prevacid 24HR, Dulcolax, Senokot and Pepto-Bismol.

Click here for the complete guide.

September 20, 2012
P&G punches up Prilosec OTC offering with wildberry flavoring

Procter & Gamble this week will begin shipping a wildberry-flavored Prilosec OTC.

NEW YORK — Procter & Gamble this week will begin shipping a wildberry-flavored Prilosec OTC.

The proton-pump inhibitor will not come in a chewable form, however, and will feature the message "Swallow — Do Not Chew" prominently on its packaging.

September 18, 2012
NewsBytes — Generics, 9/24/12

Generic drug makers Hospira, Sagent Pharmaceuticals and Teva Pharmaceutical Industries have launched generic versions of a chemotherapy drug made by Sanofi, the three companies said last month.


NEW YORK — Generic drug makers Hospira, Sagent Pharmaceuticals and Teva Pharmaceutical Industries have launched generic versions of a chemotherapy drug made by Sanofi, the three companies said last month.


September 17, 2012
FDA approves Wockhardt generic ulcer drug

The Food and Drug Administration has approved a generic ulcer treatment made by Wockhardt, the Indian drug maker said Monday.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic ulcer treatment made by Wockhardt, the Indian drug maker said Monday.

Wockhardt announced the approval and launch of lansoprazole delayed-release capsules in the 15-mg and 30-mg strengths. The drug is a generic version of Prevacid, which Takeda markets in the United States.

The drug has a market of about $700 million in the United States, according to IMS Health.

August 17, 2012
Generics contend in PPIs

Procter & Gamble’s Prilosec OTC still is the best-selling antacid on the market, with more than $252.7 million in annual sales for the 52 weeks ended July 8 across food, drug and mass (excluding Walmart), followed by fellow proton-pump inhibitor Novartis’ Prevacid 24HR ($104.1 million).


Procter & Gamble’s Prilosec OTC still is the best-selling antacid on the market, with more than $252.7 million in annual sales for the 52 weeks ended July 8 across food, drug and mass (excluding Walmart), followed by fellow proton-pump inhibitor Novartis’ Prevacid 24HR ($104.1 million).


Both of those antacid heavy hitters are losing dollar share to their generic-
equivalent competitors, however, leaving GlaxoSmithKline’s venerable Tums brand as the largest growth brand within antacids ($91.3 million in sales, up 2.5%).


August 13, 2012
Pfizer will shepherd OTC Nexium through switch process

Pfizer will be the next consumer healthcare company to reach the market with a switched proton-pump inhibitor.

NEW YORK — Pfizer will be the next consumer healthcare company to reach the market with a switched proton-pump inhibitor. Pfizer on Monday afternoon announced that it has entered into an agreement with AstraZeneca for the over-the-counter rights to Nexium.

August 10, 2012
Mylan launches generic sleep disorder, bipolar disorder drugs

Mylan has launched a generic drug used to treat sleep disorders, the company said Friday.

PITTSBURGH — Mylan has launched a generic drug used to treat sleep disorders, the company said Friday.

The generic drug maker announced the launch of modafinil tablets in the 100-mg and 200-mg strengths. The drug is a generic version of Provigil, made by Cephalon — a company that Teva Pharmaceutical Industries acquired last year — and used to treat narcolepsy, obstructive sleep apnea and shift work disorder.

May 18, 2012
Perrigo launches store-brand Prevacid 24HR

Perrigo on Friday announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug application for lansoprazole capsules in the 15-mg strength.

ALLEGAN, Mich. — Perrigo on Friday announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug application for lansoprazole capsules in the 15-mg strength. The capsules are a generic equivalent of Novartis' Prevacid 24HR capsules.

Sales for Prevacid OTC were approximately $220 million, Perrigo reported.

Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

April 30, 2012
Mylan to launch generic version of Nuvigil in 2016

Mylan plans to start selling a generic version of a drug for sleep disorders starting in June 2016, under a deal with Teva announced Monday.

PITTSBURGH — Mylan plans to start selling a generic version of a drug for sleep disorders starting in June 2016, under a deal with Teva announced Monday.

Mylan said it had settled with Teva over the former's generic version of Nuvigil (armodafinil) tablets, a drug used to treat sleepiness related to sleep apnea, narcolepsy and shift work disorder.

April 23, 2012
Par buys rights to generic drug for GERD

Par Pharmaceutical has bought rights to a generic drug for gastroesophageal reflux disease from Handa Pharmaceuticals, Par said.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical has bought rights to a generic drug for gastroesophageal reflux disease from Handa Pharmaceuticals, Par said.

Handa, based in Fremont, Calif., sold rights to the regulatory approval application it filed with the Food and Drug Administration for dexlansoprazole capsules, a generic version of Takeda's Dexilant, in the 60-mg strength.

April 6, 2012
Par launches generic version of Provigil

Par Pharmaceutical has started shipping its generic version of a drug for sleep disorders, the company said Friday.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical has started shipping its generic version of a drug for sleep disorders, the company said Friday.

Par announced the launch of a generic version of Provigil (modafinil), used to treat such sleep disorders as narcolepsy and work shift sleep disorder.

April 5, 2012
Teva entitled to exclusivity on Provigil, FDA decides

Teva is the first company to file for a generic version of a drug to treat sleep disorders, the Food and Drug Administration has determined.

JERUSALEM — Teva is the first company to file for a generic version of a drug used to treat sleep disorders, the Food and Drug Administration has determined, though Mylan is contesting the FDA decision.

February 8, 2012
BI study: No drug interaction between Aggrenox, omeprazole

An antiplatelet medication created by Boehringer Ingelheim is not affected when co-administered with a proton-pump inhibitor, according to results of a drug interaction study.

RIDGEFIELD, Conn. — An antiplatelet medication created by Boehringer Ingelheim is not affected when co-administered with a proton-pump inhibitor, according to results of a drug interaction study.

August 25, 2011
AstraZeneca introduces Rx savings program for Nexium patients

AstraZeneca is offering a discount savings program for its prescription acid reflux disease treatment.

WILMINGTON, Del. — AstraZeneca is offering a discount savings program for its prescription acid reflux disease treatment.

The company said its new Nexium savings card is designed to offer eligible patients instant discounts on their prescriptions for the drug. AstraZeneca noted that the offer is good for up to $50 off on 12 prescriptions of at least a 30-day supply of Nexium, must be used within 14 months of the first prescription fill and cannot be combined with any other offer. Additionally, the offer is not valid for patients that have a co-pay of $18 or less.

August 9, 2011
Report: Pfizer, AstraZeneca file patent suits against Hetero

Hetero is at the center of two patent litigation suits for attempting to market generic versions of Viagra and Nexium, according to published reports.

NEW YORK — Hetero is at the center of two patent litigation suits for attempting to market generic versions of Viagra and Nexium, according to published reports.

August 3, 2011
Topco institutes OTC substitution program for generic Rx

Topco, a member-owned cooperative serving the food industry, recently kicked off an initiative substituting its TopCare-branded over-the-counter medicines for the equivalent prescription pharmaceutical, where appropriate, in an effort to save patient dollars and promote the TopCare brand.

SKOKIE, Ill. — Topco, a member-owned cooperative serving the food industry, recently kicked off an initiative substituting its TopCare-branded over-the-counter medicines for the equivalent prescription pharmaceutical, where appropriate, in an effort to save patient dollars and promote the TopCare brand.

April 25, 2011
Pozen, AstraZeneca file suit against Dr. Reddy's over generic Vimovo

A generic drug maker is being sued for patent infringement for its version of a fixed-dose combination drug co-created by Pozen and AstraZeneca.

CHAPEL HILL, N.C. — A generic drug maker is being sued for patent infringement for its version of a fixed-dose combination drug co-created by Pozen and AstraZeneca.